Live-attenuated Yersinia pestis vaccines

References

• Morelli G, Song Y, Mazzoni CJ et al. Yersinia pestis genome sequencing identifies patterns of global phylogenetic diversity. Nat. Genet. 42(12), 1140–1143 (2010).
   PubMed Web of Science ®Google Scholar
• Cui Y, Yu C, Yan Y et al. Historical variations in mutation rate in an epidemic pathogen, Yersinia pestis. Proc. Natl Acad. Sci. USA 110(2), 577–582 (2012).
   Google Scholar
• Perry RD, Fetherston JD. Yersinia pestis – etiologic agent of plague. Clin. Microbiol. Rev. 10(1), 35–66 (1997).
   PubMed Web of Science ®Google Scholar
• Wang H, Cui Y, Wang Z et al. A dog-associated primary pneumonic plague in Qinghai Province, China. Clin. Infect. Dis. 52(2), 185–190 (2011).
   PubMedGoogle Scholar
• Zietz BP, Dunkelberg H. The history of the plague and the research on the causative agent Yersinia pestis. Int. J. Hyg. Environ. Health 207(2), 165–178 (2004).
   PubMed Web of Science ®Google Scholar
• WHO. Human plague in 1998 and 1999. Wkly Epidemiol. Rec. 75(42), 338–343 (2000).
   Google Scholar
• WHO. Human plague in 2002 and 2003. Wkly Epidemiol. Rec. 79(33), 301–306 (2004).
   Google Scholar
• Williamson ED. Plague vaccine research and development. J. Appl. Microbiol. 91(4), 606–608 (2001).
   PubMed Web of Science ®Google Scholar
• Riedel S. Plague: from natural disease to bioterrorism. Proc. (Bayl. Univ. Med. Cent.) 18(2), 116–124 (2005).
   PubMedGoogle Scholar
• Jezek Z. [Bioterrorism–a public and health threat]. Epidemiol. Mikrobiol. Imunol. 49(4), 165–173 (2000).
   Google Scholar
• Galimand M, Guiyoule A, Gerbaud G et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N. Engl. J. Med. 337(10), 677–680 (1997).
   PubMed Web of Science ®Google Scholar
• Guiyoule A, Gerbaud G, Buchrieser C et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerging Infect. Dis. 7(1), 43–48 (2001).
   PubMed Web of Science ®Google Scholar
• Russell P, Eley SM, Hibbs SE, Manchee RJ, Stagg AJ, Titball RW. A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 13(16), 1551–1556 (1995).
   PubMed Web of Science ®Google Scholar
• Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin. Biol. Ther. 4(6), 965–973 (2004).
   PubMed Web of Science ®Google Scholar
• Parent MA, Berggren KN, Kummer LW et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect. Immun. 73(11), 7304–7310 (2005).
   PubMed Web of Science ®Google Scholar
• Philipovskiy AV, Smiley ST. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect. Immun. 75(2), 878–885 (2007).
   PubMed Web of Science ®Google Scholar
• Morton M, Garmory HS, Perkins SD et al. A Salmonella enterica serovar Typhi vaccine expressing Yersinia pestis F1 antigen on its surface provides protection against plague in mice. Vaccine 22(20), 2524–2532 (2004).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Eley SM, Griffin KF et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol. Med. Microbiol. 12(3–4), 223–230 (1995).
   PubMedGoogle Scholar
• Rosenzweig JA, Chopra AK. The future of plague vaccines: hopes raised by a surrogate, live-attenuated recombinant vaccine candidate. Expert Rev. Vaccines 11(6), 659–661 (2012).
   PubMed Web of Science ®Google Scholar
• Derbise A, Cerdà Marín A, Ave P et al. An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague. PLoS Negl. Trop. Dis. 6(2), e1528 (2012).
   Google Scholar
• Sizemore DR, Warner EA, Lawrence JA, Thomas LJ, Roland KL, Killeen KP. Construction and screening of attenuated dphoP/Q Salmonella typhimurium vectored plague vaccine candidates. Hum. Vaccin. Immunother. 8(3), 371–383 (2012).
   PubMed Web of Science ®Google Scholar
• Mizel SB, Graff AH, Sriranganathan N et al. Flagellin–F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin. Vaccine Immunol. 16(1), 21–28 (2009).
   PubMed Web of Science ®Google Scholar
• Du Y, Rosqvist R, Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect. Immun. 70(3), 1453–1460 (2002).
   PubMed Web of Science ®Google Scholar
• Karlyshev AV, Galyov EE, Abramov VM, Zav’yalov VP. Caf1R gene and its role in the regulation of capsule formation of Y. pestis. FEBS Lett. 305(1), 37–40 (1992).
   Google Scholar
• Overheim KA, Depaolo RW, Debord KL et al. LcrV plague vaccine with altered immunomodulatory properties. Infect. Immun. 73(8), 5152–5159 (2005).
   Google Scholar
• Garmory HS, Freeman D, Brown KA, Titball RW. Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen. Vaccine 22(8), 947–957 (2004).
   PubMed Web of Science ®Google Scholar
• Grosfeld H, Cohen S, Bino T et al. Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect. Immun. 71(1), 374–383 (2003).
   PubMed Web of Science ®Google Scholar
• Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb. Pathog. 23(3), 167–179 (1997).
   PubMed Web of Science ®Google Scholar
• Wang S, Heilman D, Liu F et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 22(25–26), 3348–3357 (2004).
   PubMed Web of Science ®Google Scholar
• Friedlander AM, Welkos SL, Worsham PL et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin. Infect. Dis. 21(Suppl. 2), S178–S181 (1995).
   PubMed Web of Science ®Google Scholar
• Heath DG, Anderson GW Jr, Mauro JM et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16(11–12), 1131–1137 (1998).
   PubMed Web of Science ®Google Scholar
• Bashaw J, Norris S, Weeks S, Trevino S, Adamovicz JJ, Welkos S. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin. Vaccine Immunol. 14(5), 605–616 (2007).
   PubMedGoogle Scholar
• Smiley ST. Current challenges in the development of vaccines for pneumonic plague. Expert Rev. Vaccines 7(2), 209–221 (2008).
   PubMed Web of Science ®Google Scholar
• Qi Z, Zhou L, Zhang Q et al. Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270. Vaccine 28(6), 1655–1660 (2009).
   Google Scholar
• Do Y, Park CG, Kang YS et al. Broad T-cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur. J. Immunol. 38(1), 20–29 (2008).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Eley SM, Stagg AJ, Green M, Russell P, Titball RW. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 15(10), 1079–1084 (1997).
   PubMed Web of Science ®Google Scholar
• Smiley ST. Immune defense against pneumonic plague. Immunol. Rev. 225, 256–271 (2008).
   PubMed Web of Science ®Google Scholar
• Bennett AM, Phillpotts RJ, Perkins SD, Jacobs SC, Williamson ED. Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan equine encephalitis virus. Vaccine 18(7–8), 588–596 (1999).
   PubMedGoogle Scholar
• Feodorova VA, Motin VL. Vaccines Against Bacterial Biothreat Pathogens. Research Signpost, Kerala, India, 175–233 (2011).
   Google Scholar
• Burrows TW, Jackson S. The virulence-enhancing effect of iron on nonpigmented mutants of virulent strains of Pasteurella pestis. Br. J. Exp. Pathol. 37(6), 577–583 (1956).
   Google Scholar
• Otten L. Immunization against plague with vaccines. Ind. J. Med. Res. 24, 73–101 (1936).
   Google Scholar
• Burrows TW, Bacon GA. The effects of loss of different virulence determinants on the virulence and immunogenicity of strains of Pasteurella pestis. Br. J. Exp. Pathol. 39(3), 278–291 (1958).
   PubMedGoogle Scholar
• Burrows TW, Jackson S. The pigmentation of Pasteurella pestis on a defined medium containing haemin. Br. J. Exp. Pathol. 37(6), 570–576 (1956).
   Google Scholar
• Girard G. [Immunity in plague. Acquisitions supplied by 30 years of work on the ‘Pasteurella pestis EV’ (girard and robic) strain]. Biol. Med. (Paris) 52, 631–731 (1963).
   PubMedGoogle Scholar
• Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull. World Health Organ. 42(5), 653–666 (1970).
   PubMed Web of Science ®Google Scholar
• Bearden SW, Fetherston JD, Perry RD. Genetic organization of the yersiniabactin biosynthetic region and construction of avirulent mutants in Yersinia pestis. Infect. Immun. 65(5), 1659–1668 (1997).
   PubMed Web of Science ®Google Scholar
• Chen TH, Elberg SS, Eisler DM. Immunity in plague: protection of the vervet (Cercopithecus aethips) against pneumonic plague by the oral administration of live-attenuated Yersinia pestis. J. Infect. Dis. 135(2), 289–293 (1977).
   Google Scholar
• Burrows TW. Virulence of Pasteurella pestis and immunity to plague. Ergeb. Mikrobiol. Immunitatsforsch. Exp. Ther. 37, 59–113 (1963).
   PubMedGoogle Scholar
• Medinski G, Razumeenko T. Allergy caused by vaccination with live plague vaccine. J. Microbiol. Epidemiol. Immunobiol. 28, 1054–1055 (1957).
   Google Scholar
• Surgalla MJ, Beesley ED, Albizo JM. Practical applications of new laboratory methods for plague investigations. Bull. World Health Organ. 42(6), 993–997 (1970).
   Google Scholar
• Welkos S, Pitt ML, Martinez M, Friedlander A, Vogel P, Tammariello R. Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague. Vaccine 20(17–18), 2206–2214 (2002).
   PubMed Web of Science ®Google Scholar
• Fetherston JD, Schuetze P, Perry RD. Loss of the pigmentation phenotype in Yersinia pestis is due to the spontaneous deletion of 102 kb of chromosomal DNA which is flanked by a repetitive element. Mol. Microbiol. 6(18), 2693–2704 (1992).
   PubMed Web of Science ®Google Scholar
• Saltykova RA, Faibich MM. [Experience from a 30-year study of the stability of the properties of the plague vaccine strain EV in the USSR]. Zh. Mikrobiol. Epidemiol. Immunobiol. 6, 3–8 (1975).
   Google Scholar
• Feodorova VA, Corbel MJ. Prospects for new plague vaccines. Expert Rev. Vaccines 8(12), 1721–1738 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou D, Han Y, Dai E et al. Defining the genome content of live plague vaccines by use of whole-genome DNA microarray. Vaccine 22(25–26), 3367–3374 (2004).
   Google Scholar
• Petersen S, Young GM. Essential role for cyclic AMP and its receptor protein in Yersinia enterocolitica virulence. Infect. Immun. 70(7), 3665–3672 (2002).
   Google Scholar
• Zhan L, Han Y, Yang L et al. The cyclic AMP receptor protein, CRP, is required for both virulence and expression of the minimal CRP regulon in Yersinia pestis biovar microtus. Infect. Immun. 76(11), 5028–5037 (2008).
   PubMed Web of Science ®Google Scholar
• Sun W, Roland KL, Kuang X, Branger CG, Curtiss R 3rd. Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague. Infect. Immun. 78(3), 1304–1313 (2010).
   PubMedGoogle Scholar
• Robinson VL, Oyston PC, Titball RW. A dam mutant of Yersinia pestis is attenuated and induces protection against plague. FEMS Microbiol. Lett. 252(2), 251–256 (2005).
   PubMedGoogle Scholar
• Sambandamurthy VK, Jacobs WR Jr. Live-attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. 7(5–6), 955–961 (2005).
   PubMed Web of Science ®Google Scholar
• Ravichandran M, Ali SA, Rashid NH et al. Construction and evaluation of a O139 Vibrio cholerae vaccine candidate based on a hemA gene mutation. Vaccine 24(18), 3750–3761 (2006).
   PubMedGoogle Scholar
• Chase CJ, Ulrich MP, Wasieloski LP Jr et al. Real-time PCR assays targeting a unique chromosomal sequence of Yersinia pestis. Clin. Chem. 51(10), 1778–1785 (2005).
   Google Scholar
• Pechous RD, McCarthy TR, Mohapatra NP et al. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS ONE 3(6), e2487 (2008).
   PubMed Web of Science ®Google Scholar
• Oyston PC, Russell P, Williamson ED, Titball RW. An aroA mutant of Yersinia pestis is attenuated in guinea-pigs, but virulent in mice. Microbiology (Reading, Engl.) 142(Pt 7), 1847–1853 (1996).
   PubMedGoogle Scholar
• Oyston PC, Mellado-Sanchez G, Pasetti MF, Nataro JP, Titball RW, Atkins HS. A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection. Microb. Pathog. 48(5), 191–195 (2010).
   Google Scholar
• Bleves S, Cornelis GR. How to survive in the host: the Yersinia lesson. Microbes Infect. 2(12), 1451–1460 (2000).
   PubMed Web of Science ®Google Scholar
• Cornelis GR. The Yersinia Ysc–Yop virulence apparatus. Int. J. Med. Microbiol. 291(6–7), 455–462 (2002).
   Google Scholar
• Schubot FD, Jackson MW, Penrose KJ et al. Three-dimensional structure of a macromolecular assembly that regulates type III secretion in Yersinia pestis. J. Mol. Biol. 346(4), 1147–1161 (2005).
   PubMed Web of Science ®Google Scholar
• Cornelis GR. Yersinia type III secretion: send in the effectors. J. Cell Biol. 158(3), 401–408 (2002).
   PubMed Web of Science ®Google Scholar
• Bubeck SS, Dube PH. Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine. Clin. Vaccine Immunol. 14(9), 1235–1238 (2007).
   PubMedGoogle Scholar
• Flashner Y, Mamroud E, Tidhar A et al. Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates. Infect. Immun. 72(2), 908–915 (2004).
   PubMed Web of Science ®Google Scholar
• Tidhar A, Flashner Y, Cohen S et al. The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague. PLoS ONE 4(9), e7023 (2009).
   PubMed Web of Science ®Google Scholar
• Sun W, Roland KL, Branger CG, Kuang X, Curtiss R 3rd. The role of relA and spoT in Yersinia pestis KIM5 pathogenicity. PLoS ONE 4(8), e6720 (2009).
   Google Scholar
• Zauberman A, Tidhar A, Levy Y et al. Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS ONE 4(6), e5938 (2009).
   Google Scholar
• Bozue J, Cote CK, Webster W et al. A Yersinia pestis YscN ATPase mutant functions as a live-attenuated vaccine against bubonic plague in mice. FEMS Microbiol. Lett. 332(2), 113–121 (2012).
   Google Scholar
• Knirel YA, Lindner B, Vinogradov EV et al. Temperature-dependent variations and intraspecies diversity of the structure of the lipopolysaccharide of Yersinia pestis. Biochemistry 44(5), 1731–1743 (2005).
   PubMedGoogle Scholar
• Rebeil R, Ernst RK, Gowen BB, Miller SI, Hinnebusch BJ. Variation in lipid A structure in the pathogenic yersiniae. Mol. Microbiol. 52(5), 1363–1373 (2004).
   PubMed Web of Science ®Google Scholar
• Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71, 635–700 (2002).
   PubMed Web of Science ®Google Scholar
• Montminy SW, Khan N, McGrath S et al. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response. Nat. Immunol. 7(10), 1066–1073 (2006).
   PubMed Web of Science ®Google Scholar
• Feodorova VA, Pan’kina LN, Savostina EP et al. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs. Vaccine 25(44), 7620–7628 (2007).
   PubMed Web of Science ®Google Scholar
• Anisimov AP, Shaikhutdinova RZ, Pan’kina LN et al. Effect of deletion of the lpxM gene on virulence and vaccine potential of Yersinia pestis in mice. J. Med. Microbiol. 56(Pt 4), 443–453 (2007).
   PubMedGoogle Scholar
• Feodorova VA, Pan’kina LN, Savostina EP et al. Pleiotropic effects of the lpxM mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens. Vaccine 27(16), 2240–2250 (2009).
   PubMed Web of Science ®Google Scholar
• Szaba FM, Kummer LW, Wilhelm LB et al. D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague. Infect. Immun. 77(10), 4295–4304 (2009).
   PubMed Web of Science ®Google Scholar
• Sun W, Six D, Kuang X, Roland KL, Raetz CR, Curtiss R 3rd. A live-attenuated strain of Yersinia pestis KIM as a vaccine against plague. Vaccine 29(16), 2986–2998 (2011).
   PubMedGoogle Scholar
• Gueneau de Novoa P, Williams KP. The tmRNA website:reductive evolution of tmRNA in plastids and other endosymbionts. Nucleic Acids Res. 32, D104–D108 (2004).
   PubMed Web of Science ®Google Scholar
• Keiler KC. Biology of trans-translation. Annu. Rev. Microbiol. 62, 133–151 (2008).
   PubMed Web of Science ®Google Scholar
• Withey JH, Friedman DI. The biological roles of trans-translation. Curr. Opin. Microbiol. 5(2), 154–159 (2002).
   Google Scholar
• Okan NA, Mena P, Benach JL, Bliska JB, Karzai AW. The smpB–ssrA mutant of Yersinia pestis functions as a live-attenuated vaccine to protect mice against pulmonary plague infection. Infect. Immun. 78(3), 1284–1293 (2010).
   PubMed Web of Science ®Google Scholar
• Benner GE, Andrews GP, Byrne WR et al. Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice. Infect. Immun. 67(4), 1922–1928 (1999).
   PubMed Web of Science ®Google Scholar
• Andrews GP, Strachan ST, Benner GE et al. Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis. Infect. Immun. 67(3), 1533–1537 (1999).
   PubMed Web of Science ®Google Scholar
• Leary SE, Williamson ED, Griffin KF, Russell P, Eley SM, Titball RW. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect. Immun. 63(8), 2854–2858 (1995).
   PubMed Web of Science ®Google Scholar
• Sodeinde OA, Subrahmanyam YV, Stark K, Quan T, Bao Y, Goguen JD. A surface protease and the invasive character of plague. Science 258(5084), 1004–1007 (1992).
   PubMed Web of Science ®Google Scholar
• Lähteenmäki K, Virkola R, Sarén A, Emödy L, Korhonen TK. Expression of plasminogen activator pla of Yersinia pestis enhances bacterial attachment to the mammalian extracellular matrix. Infect. Immun. 66(12), 5755–5762 (1998).
   PubMed Web of Science ®Google Scholar
• Welkos SL, Friedlander AM, Davis KJ. Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092. Microb. Pathog. 23(4), 211–223 (1997).
   Google Scholar
• Hantke K, Braun V. Covalent binding of lipid to protein. Diglyceride and amide-linked fatty acid at the N-terminal end of the murein-lipoprotein of the Escherichia coli outer membrane. Eur. J. Biochem. 34(2), 284–296 (1973).
   PubMedGoogle Scholar
• Sha J, Agar SL, Baze WB et al. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect. Immun. 76(4), 1390–1409 (2008).
   PubMed Web of Science ®Google Scholar
• Sun W, Roland KL, Curtiss R 3rd. Developing live vaccines against plague. J. Infect. Dev. Ctries. 5(9), 614–627 (2011).
   PubMed Web of Science ®Google Scholar
• Rosenzweig JA, Jejelowo O, Sha J et al. Progress on plague vaccine development. Appl. Microbiol. Biotechnol. 91(2), 265–286 (2011).
   PubMed Web of Science ®Google Scholar
• Frank KM, Schneewind O, Shieh WJ. Investigation of a researcher’s death due to septicemic plague. N. Engl. J. Med. 364(26), 2563–2564 (2011).
   PubMedGoogle Scholar